검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | PD-1 and PD-L1 inhibitor |
Overview Company | Atreca, Inc. |
Overview Modality | ADC |
Overview Target | PD-1 |
Overview Indication | Immune-related Adverse Event; Malignant Solid Tumors |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway |
MoA Biomarker | biomarker for risk stratification and timely cardioprotective intervention |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Early prediction of synergistic cardiotoxicity induced by PD-1 inhibitors and doxorubicin using cardiac 18 F-FDG PET/MRI.. Early detection of synergistic cardiotoxicity induced by sequential anthracycline and programmed cell death protein 1 (PD-1) inhibitor therapy remains challenging because conventional assessments identify late-stage functional impairment. This study aimed to determine the sens… |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | PD-1 and PD-L1 inhibitor |
Overview Company | Atreca, Inc. |
Overview Modality | ADC |
Overview Target | PD-1 |
Overview Indication | Immune-related Adverse Event; Malignant Solid Tumors |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway |
MoA Biomarker | biomarker for risk stratification and timely cardioprotective intervention |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Early prediction of synergistic cardiotoxicity induced by PD-1 inhibitors and doxorubicin using cardiac 18 F-FDG PET/MRI.. Early detection of synergistic cardiotoxicity induced by sequential anthracycline and programmed cell death protein 1 (PD-1) inhibitor therapy remains challenging because conventional assessments identify late-stage functional impairment. This study aimed to determine the sens… |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교